In 342 patients with untreated unresectable hepatocellular carcinoma, adding atezolizumab plus bevacizumab to on-demand TACE lengthened median TACE-PFS (11.3 vs 7.0 months; HR 0.71). Overall survival, immature at interim analysis, showed no difference (HR 0.96).
RCTn = 342
Kudo et al. On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial